Company News: Dendreon

Share this article:
Dendreon's Provenge prostate cancer vaccine, the first in a new class of cancer treatments that use the patient's own immune system, received FDA approval. The vaccine, approved for men with the advanced form of the disease, is designed to induce an immune response against prostatic acid phosphatase, an antigen expressed in most prostate cancers. Provenge (sipuleucel-T) belongs to a new therapeutic class called autologous cellular immunotherapies and could usher in an entirely new treatment paradigm for patients with cancer. Several other companies are developing immunotherapies targeting tumor antigens.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.